Profile data is unavailable for this security.
About the company
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
- Revenue in USD (TTM)0.00
- Net income in USD-128.91m
- Incorporated2010
- Employees93.00
- LocationX4 Pharmaceuticals Inc61 NORTH BEACON STREET, 4TH FLOORBOSTON 02134United StatesUSA
- Phone+1 (857) 529-8300
- Fax+1 (302) 655-5049
- Websitehttps://www.x4pharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Werewolf Therapeutics Inc | 16.22m | -41.58m | 127.76m | 46.00 | -- | 1.08 | -- | 7.88 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
aTyr Pharma Inc | 588.00k | -53.93m | 129.05m | 56.00 | -- | 1.51 | -- | 219.47 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
Athira Pharma Inc | 0.00 | -116.19m | 129.17m | 65.00 | -- | 1.21 | -- | -- | -3.05 | -3.05 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -63.45 | -30.73 | -72.51 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 130.26m | 127.00 | -- | 1.64 | -- | 26.05 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
CervoMed Inc | 9.49m | -593.84k | 131.23m | 8.00 | 8.06 | 18.39 | -- | 13.83 | 1.97 | 1.97 | 2.04 | 0.8648 | 0.719 | -- | -- | 1,186,515.00 | -4.50 | -53.67 | -5.49 | -58.89 | -- | -- | -6.26 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
Immunic Inc | 0.00 | -97.92m | 131.52m | 77.00 | -- | 1.57 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
X4 Pharmaceuticals Inc | 0.00 | -128.91m | 138.58m | 93.00 | -- | 133.77 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 139.49m | 28.00 | -- | 3.28 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
CytoDyn Inc | 0.00 | -51.69m | 140.26m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
Compass Therapeutics Inc. | 0.00 | -45.44m | 141.72m | 32.00 | -- | 0.9023 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
Agenus Inc | 161.42m | -239.61m | 145.10m | 389.00 | -- | -- | -- | 0.899 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
DiaMedica Therapeutics Inc | 0.00 | -19.26m | 147.03m | 18.00 | -- | 2.82 | -- | -- | -0.5532 | -0.5532 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -48.47 | -45.38 | -52.02 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
Elevation Oncology Inc | 0.00 | -39.35m | 147.52m | 29.00 | -- | 1.84 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
Invivyd Inc | 0.00 | -206.82m | 149.14m | 94.00 | -- | 0.8349 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Personalis Inc | 74.15m | -92.61m | 149.58m | 223.00 | -- | 1.23 | -- | 2.02 | -1.89 | -1.89 | 1.51 | 2.35 | 0.3172 | 6.50 | 5.04 | 332,493.30 | -39.62 | -28.84 | -46.08 | -34.72 | 25.59 | 28.65 | -124.90 | -96.01 | 3.56 | -- | 0.0209 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 8.06m | 4.80% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 7.66m | 4.56% |
Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 4.58m | 2.73% |
Adage Capital Management LPas of 31 Mar 2024 | 4.28m | 2.55% |
Sio Capital Management LLCas of 31 Mar 2024 | 3.59m | 2.14% |
Perceptive Advisors LLCas of 31 Mar 2024 | 3.55m | 2.11% |
Kingdon Capital Management LLCas of 31 Mar 2024 | 3.47m | 2.07% |
AXA Investment Managers UK Ltd.as of 31 Mar 2024 | 3.07m | 1.83% |
Geode Capital Management LLCas of 31 Mar 2024 | 2.95m | 1.75% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.52m | 1.50% |